December 1-4 marked the annual ASH Annual Meeting and Exposition. Leading experts convened in San Diego, CA to address the latest news and research updates in chronic lymphocytic leukemia.
Loretta J Nastoupil, MD, The University of Texas MD Anderson Cancer Center, considers the findings of the ZUMA-1 study and their comparability to real-world outcomes in patients with large B-cell lymphoma receiving CAR-T therapy.
Chadi Nabhan, MD, Cardinal Health, discusses adverse events, patterns of TLS prophylaxis and management, and dosing patterns in patients with CLL treated in community and academic settings.
Gunjan L Shah, MD, MS, Memorial Sloan Kettering Cancer Center, explains how increasing use of CAR-T therapy can create challenges in institutional resource capacity and how identifying these resources will allow for better care delivery and allocation of funds.
Failure on Daratumumab-Based Therapy in Multiple Myeloma: A Pooled Analysis of PREAMBLE, McKesson's EMR
Ravi Vij, MD, MBA, discusses real-world findings related to patients with relapsed or refractory multiple myelomaafter daratumumab treatment from a pooled dataanalysis, PREAMBLE, and the McKesson electronic medical record database.
Is CAR-T Therapy Comparable to Past Innovative Therapies in Regard to Health Outcomes, Cost-Effectiveness?
James Baumgardner, PhD, discusses how CAR-Ttherapy displays favorable gains in health outcomes and competitive cost-effectiveness when compared with pastinnovative cancer treatments.
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, discusses the larger implications of the BEAT AML Master Trial, which examined a novel treatment option for previously untreated IDH2-mutant AML.
Matthew S Davids, MD, MMSc, discusses a presentation at the ASH Annual Meeting and Exposition about the CLL Society’s exploration of how patients with CLL make therapy decisions.
Jeff Sharman, MD, Anthony Mato, MD, MSCE, and Chaitra Ujjani, MD, converse at the ASH Annual Meeting and Exposition about the findings of an interim analysis from the prospective informCLL real-world registry and optimizing CLL treatment in real-world practice.
A new scoring system model may be a valid tool for identifying patients with CLL at higher risk of developing atrial fibrillation, including those treated with a targeted therapy.
A study shed light on a “considerable lack” of prognostic marker testing among patients with CLL in the modern era.
A survey showed that most patients with CLL want to be involved in therapy decisions and that gender, age, and therapy status influence decision-making.